<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (systemic <z:hpo ids='HP_0100324'>scleroderma</z:hpo>) is a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> of unknown etiology that causes widespread microvascular damage and excessive deposition of collagen in the skin and internal organs </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud phenomenon</z:e> and <z:hpo ids='HP_0100324'>scleroderma</z:hpo> (hardening of the skin) are hallmarks of the disease </plain></SENT>
<SENT sid="2" pm="."><plain>The typical patient is a young or middle-age woman with a history of <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud phenomenon</z:e> who presents with <z:e sem="disease" ids="C0241075" disease_type="Disease or Syndrome" abbrv="">skin induration</z:e> and internal organ dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical evaluation and laboratory testing, along with pulmonary function testing, Doppler echocardiography, and high-resolution computed tomography of the chest, establish the diagnosis and detect visceral involvement </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> can be classified into two distinct clinical subsets with different patterns of skin and internal organ involvement, autoantibody production, and survival </plain></SENT>
<SENT sid="5" pm="."><plain>Prognosis is determined by the degree of internal organ involvement </plain></SENT>
<SENT sid="6" pm="."><plain>Although no disease-modifying therapy has been proven effective, complications of systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> are treatable, and interventions for organ-specific manifestations have improved substantially </plain></SENT>
<SENT sid="7" pm="."><plain>Medications (e.g., <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi> and <z:chebi fb="0" ids="2719,48432">angiotensin-II</z:chebi> receptor blockers for <z:e sem="disease" ids="C0034735" disease_type="Disease or Syndrome" abbrv="">Raynaud phenomenon</z:e>, appropriate treatments for <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo>) and lifestyle modifications can help prevent complications, such as digital <z:mpath ids='MPATH_579'>ulcers</z:mpath> and <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Endothelin-1 receptor blockers and phosphodiesterase-5 inhibitors improve pulmonary arterial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The risk of renal damage from <z:hpo ids='HP_0100324'>scleroderma</z:hpo> renal crisis can be lessened by early detection, prompt initiation of <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> therapy, and avoidance of high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Optimal patient care includes an integrated, multidisciplinary approach to promptly and effectively recognize, evaluate, and manage complications and limit end-organ dysfunction </plain></SENT>
</text></document>